Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient

Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

Alberto Zanchetti, Lisheng Liu, Giuseppe Mancia, Gianfranco Parati, Guido Grassi, Marco Stramba-Badiale, Vincenzo Silani, Grzegorz Bilo, Giovanni Corrao, Antonella Zambon, Lorenza Scotti, Xinhua Zhang, Hayyan Wang, Yuqing Zhang, Xuezhong Zhang, Ting Rui Guan, Eivind Berge, Josep Redon, Krzysztof Narkiewicz, Anna Dominiczak & 33 others Peter Nilsson, Margus Viigimaa, Stéphane Laurent, Enrico Agabiti-Rosei, Zhaosu Wu, Dingliang Zhu, José Luis Rodicio, Luis Miguel Ruilope, Nieves Martell-Claros, Fernando Pinto, Roland E. Schmieder, Michel Burnier, Maciej Banach, Renata Cifkova, Csaba Farsang, Alexandra Konradi, Irina Lazareva, Yuriy Sirenko, Maria Dorobantu, Arman Postadzhiyan, Rok Accetto, Bojan Jelakovic, Dragan Lovic, Athanasios J. Manolis, Philippos Stylianou, Serap Erdine, Dror Dicker, Gangzhi Wei, Chengbin Xu, Hengge Xie, Antonio Coca, John O'Brien, Gary Ford

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1,

Original languageEnglish
Pages (from-to)1888-1897
Number of pages10
JournalJournal of Hypertension
Volume32
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

LDL Cholesterol
Stroke
Blood Pressure
Hypertension
Antihypertensive Agents
Transient Ischemic Attack
Therapeutics
Uncertainty
Cognitive Dysfunction

Keywords

  • blood pressure
  • cognitive decline
  • low-density lipoprotein cholesterol
  • randomized controlled trial
  • secondary prevention
  • stroke

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. / Zanchetti, Alberto; Liu, Lisheng; Mancia, Giuseppe; Parati, Gianfranco; Grassi, Guido; Stramba-Badiale, Marco; Silani, Vincenzo; Bilo, Grzegorz; Corrao, Giovanni; Zambon, Antonella; Scotti, Lorenza; Zhang, Xinhua; Wang, Hayyan; Zhang, Yuqing; Zhang, Xuezhong; Guan, Ting Rui; Berge, Eivind; Redon, Josep; Narkiewicz, Krzysztof; Dominiczak, Anna; Nilsson, Peter; Viigimaa, Margus; Laurent, Stéphane; Agabiti-Rosei, Enrico; Wu, Zhaosu; Zhu, Dingliang; Rodicio, José Luis; Ruilope, Luis Miguel; Martell-Claros, Nieves; Pinto, Fernando; Schmieder, Roland E.; Burnier, Michel; Banach, Maciej; Cifkova, Renata; Farsang, Csaba; Konradi, Alexandra; Lazareva, Irina; Sirenko, Yuriy; Dorobantu, Maria; Postadzhiyan, Arman; Accetto, Rok; Jelakovic, Bojan; Lovic, Dragan; Manolis, Athanasios J.; Stylianou, Philippos; Erdine, Serap; Dicker, Dror; Wei, Gangzhi; Xu, Chengbin; Xie, Hengge; Coca, Antonio; O'Brien, John; Ford, Gary.

In: Journal of Hypertension, Vol. 32, No. 9, 2014, p. 1888-1897.

Research output: Contribution to journalArticle

Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba-Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Zhang, X, Guan, TR, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti-Rosei, E, Wu, Z, Zhu, D, Rodicio, JL, Ruilope, LM, Martell-Claros, N, Pinto, F, Schmieder, RE, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, AJ, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J & Ford, G 2014, 'Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial', Journal of Hypertension, vol. 32, no. 9, pp. 1888-1897. https://doi.org/10.1097/HJH.0000000000000254
Zanchetti, Alberto ; Liu, Lisheng ; Mancia, Giuseppe ; Parati, Gianfranco ; Grassi, Guido ; Stramba-Badiale, Marco ; Silani, Vincenzo ; Bilo, Grzegorz ; Corrao, Giovanni ; Zambon, Antonella ; Scotti, Lorenza ; Zhang, Xinhua ; Wang, Hayyan ; Zhang, Yuqing ; Zhang, Xuezhong ; Guan, Ting Rui ; Berge, Eivind ; Redon, Josep ; Narkiewicz, Krzysztof ; Dominiczak, Anna ; Nilsson, Peter ; Viigimaa, Margus ; Laurent, Stéphane ; Agabiti-Rosei, Enrico ; Wu, Zhaosu ; Zhu, Dingliang ; Rodicio, José Luis ; Ruilope, Luis Miguel ; Martell-Claros, Nieves ; Pinto, Fernando ; Schmieder, Roland E. ; Burnier, Michel ; Banach, Maciej ; Cifkova, Renata ; Farsang, Csaba ; Konradi, Alexandra ; Lazareva, Irina ; Sirenko, Yuriy ; Dorobantu, Maria ; Postadzhiyan, Arman ; Accetto, Rok ; Jelakovic, Bojan ; Lovic, Dragan ; Manolis, Athanasios J. ; Stylianou, Philippos ; Erdine, Serap ; Dicker, Dror ; Wei, Gangzhi ; Xu, Chengbin ; Xie, Hengge ; Coca, Antonio ; O'Brien, John ; Ford, Gary. / Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient : Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. In: Journal of Hypertension. 2014 ; Vol. 32, No. 9. pp. 1888-1897.
@article{60ac7db5ccbb47d6a87426cfaf103c36,
title = "Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial",
abstract = "BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1,",
keywords = "blood pressure, cognitive decline, low-density lipoprotein cholesterol, randomized controlled trial, secondary prevention, stroke",
author = "Alberto Zanchetti and Lisheng Liu and Giuseppe Mancia and Gianfranco Parati and Guido Grassi and Marco Stramba-Badiale and Vincenzo Silani and Grzegorz Bilo and Giovanni Corrao and Antonella Zambon and Lorenza Scotti and Xinhua Zhang and Hayyan Wang and Yuqing Zhang and Xuezhong Zhang and Guan, {Ting Rui} and Eivind Berge and Josep Redon and Krzysztof Narkiewicz and Anna Dominiczak and Peter Nilsson and Margus Viigimaa and St{\'e}phane Laurent and Enrico Agabiti-Rosei and Zhaosu Wu and Dingliang Zhu and Rodicio, {Jos{\'e} Luis} and Ruilope, {Luis Miguel} and Nieves Martell-Claros and Fernando Pinto and Schmieder, {Roland E.} and Michel Burnier and Maciej Banach and Renata Cifkova and Csaba Farsang and Alexandra Konradi and Irina Lazareva and Yuriy Sirenko and Maria Dorobantu and Arman Postadzhiyan and Rok Accetto and Bojan Jelakovic and Dragan Lovic and Manolis, {Athanasios J.} and Philippos Stylianou and Serap Erdine and Dror Dicker and Gangzhi Wei and Chengbin Xu and Hengge Xie and Antonio Coca and John O'Brien and Gary Ford",
year = "2014",
doi = "10.1097/HJH.0000000000000254",
language = "English",
volume = "32",
pages = "1888--1897",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient

T2 - Design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial

AU - Zanchetti, Alberto

AU - Liu, Lisheng

AU - Mancia, Giuseppe

AU - Parati, Gianfranco

AU - Grassi, Guido

AU - Stramba-Badiale, Marco

AU - Silani, Vincenzo

AU - Bilo, Grzegorz

AU - Corrao, Giovanni

AU - Zambon, Antonella

AU - Scotti, Lorenza

AU - Zhang, Xinhua

AU - Wang, Hayyan

AU - Zhang, Yuqing

AU - Zhang, Xuezhong

AU - Guan, Ting Rui

AU - Berge, Eivind

AU - Redon, Josep

AU - Narkiewicz, Krzysztof

AU - Dominiczak, Anna

AU - Nilsson, Peter

AU - Viigimaa, Margus

AU - Laurent, Stéphane

AU - Agabiti-Rosei, Enrico

AU - Wu, Zhaosu

AU - Zhu, Dingliang

AU - Rodicio, José Luis

AU - Ruilope, Luis Miguel

AU - Martell-Claros, Nieves

AU - Pinto, Fernando

AU - Schmieder, Roland E.

AU - Burnier, Michel

AU - Banach, Maciej

AU - Cifkova, Renata

AU - Farsang, Csaba

AU - Konradi, Alexandra

AU - Lazareva, Irina

AU - Sirenko, Yuriy

AU - Dorobantu, Maria

AU - Postadzhiyan, Arman

AU - Accetto, Rok

AU - Jelakovic, Bojan

AU - Lovic, Dragan

AU - Manolis, Athanasios J.

AU - Stylianou, Philippos

AU - Erdine, Serap

AU - Dicker, Dror

AU - Wei, Gangzhi

AU - Xu, Chengbin

AU - Xie, Hengge

AU - Coca, Antonio

AU - O'Brien, John

AU - Ford, Gary

PY - 2014

Y1 - 2014

N2 - BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1,

AB - BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1,

KW - blood pressure

KW - cognitive decline

KW - low-density lipoprotein cholesterol

KW - randomized controlled trial

KW - secondary prevention

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=84906089553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906089553&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000000254

DO - 10.1097/HJH.0000000000000254

M3 - Article

VL - 32

SP - 1888

EP - 1897

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 9

ER -